A 1% HbA1c reduction in diabetic retinopathy risk is one of the most clinically significant benefits of improved glycaemic control in people living with diabetes. Diabetic retinopathy — damage to the small blood vessels of the retina caused by chronically elevated blood glucose — is a leading cause of preventable sight loss in the UK. Evidence from landmark trials such as UKPDS and DCCT demonstrates that even modest, sustained reductions in HbA1c can substantially lower the risk of developing or worsening retinopathy. This article explains the evidence, relevant NICE and NHS guidance, and when to seek screening or urgent eye care.
Summary: A 1% reduction in HbA1c is associated with approximately a 37% reduction in the risk of microvascular complications including diabetic retinopathy, based on evidence from UKPDS 35.
- Each 1% (approximately 11 mmol/mol) reduction in HbA1c is linked to around a 37% reduction in microvascular complication risk, including retinopathy (UKPDS 35).
- Rapid HbA1c lowering in patients with longstanding poor control can cause a transient, short-term worsening of retinopathy, requiring closer retinal monitoring.
- NICE recommends individualised HbA1c targets: 48 mmol/mol (6.5%) for type 1 diabetes and 48–53 mmol/mol (6.5–7.0%) for type 2 diabetes, depending on treatment and hypoglycaemia risk.
- Blood pressure control, diabetes duration, dyslipidaemia, pregnancy, and nephropathy are additional independent risk factors for diabetic retinopathy progression.
- The NHS Diabetic Eye Screening Programme offers annual retinal photography to all people aged 12 and over with diabetes; referral to Hospital Eye Services is required for grades R2, R3, or M1.
- Sudden visual symptoms such as floaters, flashing lights, or a visual field shadow require same-day urgent eye assessment at A&E or eye casualty.
Table of Contents
- How HbA1c Levels Affect the Risk of Diabetic Retinopathy
- What a 1% HbA1c Reduction Means for Your Eye Health
- Evidence Behind Glycaemic Control and Retinopathy Progression
- NICE and NHS Guidelines on HbA1c Targets in Diabetes
- Other Factors That Influence Diabetic Retinopathy Risk
- When to Seek an NHS Diabetic Eye Screening Referral
- Frequently Asked Questions
How HbA1c Levels Affect the Risk of Diabetic Retinopathy
Persistently elevated HbA1c is one of the most significant modifiable risk factors for diabetic retinopathy, causing vascular damage through mechanisms including microaneurysm formation, neovascularisation, and retinal ischaemia.
Have any more questions about this? Message our pharmaceutical team to get more info →
HbA1c (glycated haemoglobin) is a measure of average blood glucose levels over the preceding two to three months. It reflects how much glucose has attached to haemoglobin in red blood cells, and is expressed as a percentage or in mmol/mol (note: 1% HbA1c is approximately 10.9 mmol/mol). In people living with diabetes — both type 1 and type 2 — persistently elevated HbA1c is one of the most significant modifiable risk factors for the development and progression of diabetic retinopathy.
Diabetic retinopathy occurs when chronically high blood glucose damages the small blood vessels supplying the retina. This damage unfolds through several mechanisms:
-
Increased vascular permeability, leading to retinal oedema
-
Microaneurysm formation, where weakened vessel walls balloon outward
-
Neovascularisation, the growth of fragile new blood vessels that can bleed into the vitreous
-
Ischaemia, caused by capillary occlusion and reduced oxygen delivery to retinal tissue
The relationship between HbA1c and retinopathy risk is broadly dose-dependent: the higher and more prolonged the elevation in HbA1c, the greater the likelihood of retinal damage. Conversely, sustained reductions in HbA1c are associated with meaningful decreases in both the incidence of new retinopathy and the rate at which existing retinopathy worsens. Understanding this relationship is central to why glycaemic management sits at the heart of diabetic eye disease prevention.
Key sources: NHS Diabetic Eye Screening Programme; Diabetes UK retinopathy information.
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
What a 1% HbA1c Reduction Means for Your Eye Health
A 1% HbA1c reduction is associated with approximately a 37% reduction in microvascular complication risk; however, rapid lowering can cause transient retinopathy worsening, so steady, sustained improvement is recommended.
A reduction of just 1% (approximately 11 mmol/mol) in HbA1c may appear modest, but the clinical implications for eye health are substantial. Landmark research — in particular UKPDS 35 — has demonstrated that even incremental improvements in long-term glycaemic control translate into meaningful reductions in microvascular complications, including diabetic retinopathy.
UKPDS 35 found that each 1% reduction in HbA1c was associated with approximately a 37% reduction in the risk of microvascular complications, a category that prominently includes retinopathy. For patients already living with early-stage retinopathy, achieving and sustaining a lower HbA1c can slow progression to more sight-threatening forms of the condition, such as proliferative diabetic retinopathy or diabetic macular oedema.
It is important to note, however, that rapid lowering of HbA1c — particularly in patients with longstanding poor control — has been associated with a transient, short-term worsening of retinopathy. This phenomenon was observed in the Diabetes Control and Complications Trial (DCCT) and is thought to result from haemodynamic changes in retinal blood flow. For this reason, clinicians and diabetes care teams should consider closer retinal monitoring when implementing major glycaemic improvements, in line with NHS Diabetic Eye Screening (DES) programme guidance and individual clinical judgement. The goal is sustained, steady improvement rather than abrupt normalisation.
Key sources: UKPDS 35 (BMJ 1998); DCCT Research Group (NEJM 1993); NHS Diabetic Eye Screening Programme guidance.
Evidence Behind Glycaemic Control and Retinopathy Progression
The DCCT showed intensive glycaemic control reduced retinopathy development by 76% in type 1 diabetes, while UKPDS confirmed similar benefits in type 2 diabetes, with a durable legacy effect from early good control.
The evidence base linking glycaemic control to retinopathy outcomes is robust and spans several decades of clinical research. The Diabetes Control and Complications Trial (DCCT), conducted in people with type 1 diabetes, demonstrated that intensive insulin therapy — which achieved lower HbA1c levels compared to conventional treatment — reduced the risk of developing retinopathy by 76% and slowed progression of existing retinopathy by 54%. Long-term follow-up through the DCCT/EDIC study confirmed that these benefits were durable.
In type 2 diabetes, the UKPDS provided complementary evidence, showing that improved glycaemic control significantly reduced the rate of retinal photocoagulation and other retinopathy-related outcomes. Long-term follow-up data from the UKPDS also revealed a legacy effect — sometimes called metabolic memory — whereby patients who achieved good early glycaemic control continued to benefit from reduced complication rates even years after the initial period of intensive management.
More recent studies, including the ACCORD Eye Study (NEJM 2010) and the ADVANCE trial (NEJM 2008), have further refined our understanding. These trials suggest that whilst intensive glycaemic control reduces retinopathy progression, the benefits must be balanced against the risks of hypoglycaemia and other adverse effects, particularly in older patients or those with cardiovascular comorbidities. NICE guidance (NG17 for type 1 diabetes; NG28 for type 2 diabetes) reflects this by recommending individualised HbA1c targets that account for hypoglycaemia risk and patient circumstances.
Taken together, the evidence strongly supports a target-driven, individualised approach to HbA1c management as a cornerstone of retinopathy prevention.
Key sources: DCCT Research Group (NEJM 1993); DCCT/EDIC follow-up; UKPDS trial reports and legacy effect analyses; ACCORD Eye Study (NEJM 2010); ADVANCE (NEJM 2008); NICE NG17; NICE NG28.
NICE and NHS Guidelines on HbA1c Targets in Diabetes
NICE recommends an HbA1c target of 48 mmol/mol (6.5%) for type 1 diabetes and 48–53 mmol/mol (6.5–7.0%) for type 2 diabetes, with targets individualised according to hypoglycaemia risk and patient circumstances.
NICE provides clear, evidence-based guidance on HbA1c targets for people living with diabetes in the UK.
For adults with type 2 diabetes (NICE NG28):
-
An HbA1c target of 48 mmol/mol (6.5%) is recommended where diabetes is managed with lifestyle measures alone or with agents not associated with hypoglycaemia (for example, metformin).
-
A target of 53 mmol/mol (7.0%) is appropriate where treatment includes drugs associated with hypoglycaemia, such as insulin or sulphonylureas.
-
Where HbA1c remains persistently at or above 58 mmol/mol (7.5%), treatment intensification should be considered, if clinically appropriate.
For adults with type 1 diabetes (NICE NG17), an HbA1c of 48 mmol/mol (6.5%) is recommended if this can be achieved safely without problematic hypoglycaemia. Targets should always be individualised, taking into account the patient's age, comorbidities, treatment regimen, and personal preferences.
Key principles from NICE and NHS guidance include:
-
Avoid a one-size-fits-all approach — targets should be agreed collaboratively with the patient
-
Review HbA1c at least every 3–6 months when treatment is being adjusted, and every 6 months once stable
-
Consider the risk of hypoglycaemia when intensifying therapy, particularly in elderly patients or those on insulin or sulphonylureas
-
Refer to structured education programmes such as DESMOND (type 2) or DAFNE (type 1) to support self-management
Achieving NICE-recommended HbA1c targets is directly relevant to retinopathy risk reduction, and diabetes care teams should ensure that eye health outcomes are considered alongside cardiovascular and renal endpoints when setting glycaemic goals.
Key sources: NICE NG28 (Type 2 diabetes in adults); NICE NG17 (Type 1 diabetes in adults).
| Evidence Source | Population | Key Finding | Retinopathy Outcome | Clinical Implication |
|---|---|---|---|---|
| UKPDS 35 (BMJ 1998) | Type 2 diabetes | Each 1% (≈11 mmol/mol) HbA1c reduction | ~37% reduction in microvascular complication risk, including retinopathy | Even modest HbA1c improvements yield significant eye-health benefit |
| DCCT (NEJM 1993) | Type 1 diabetes | Intensive vs conventional insulin therapy | 76% reduced risk of new retinopathy; 54% slower progression of existing retinopathy | Intensive glycaemic control substantially protects retinal health in type 1 diabetes |
| DCCT/EDIC follow-up | Type 1 diabetes | Long-term follow-up post-DCCT | Durable retinopathy benefits persisted after trial end (legacy/metabolic memory effect) | Early sustained control confers lasting protection even after intensive phase ends |
| DCCT (NEJM 1993) — caution | Type 1 diabetes, poor prior control | Rapid HbA1c reduction | Transient short-term worsening of retinopathy observed | Closer retinal monitoring advised when implementing major glycaemic improvements |
| ACCORD Eye Study (NEJM 2010) | Type 2 diabetes, high CV risk | Intensive vs standard glycaemic control | Reduced retinopathy progression, but hypoglycaemia risk increased | Benefits must be balanced against hypoglycaemia risk, especially in older patients |
| UKPDS BP sub-study | Type 2 diabetes | Tight blood pressure control | 34% reduction in retinopathy progression | Blood pressure management is a key adjunct to HbA1c control for retinopathy prevention |
| NICE NG17 / NG28 | Type 1 & type 2 diabetes (UK) | Recommended HbA1c targets: 48 mmol/mol (6.5%) or 53 mmol/mol (7.0%) | Achieving targets reduces microvascular risk including retinopathy | Individualise targets; consider hypoglycaemia risk, age, and comorbidities |
Other Factors That Influence Diabetic Retinopathy Risk
Blood pressure, diabetes duration, dyslipidaemia, pregnancy, nephropathy, smoking, and ethnicity all independently influence retinopathy risk alongside HbA1c, requiring a holistic management approach.
Whilst HbA1c is a critical determinant of retinopathy risk, it is not the only factor. Diabetic retinopathy is a multifactorial condition, and several other variables contribute independently to its development and progression.
Blood pressure control is particularly important. Hypertension accelerates retinal vascular damage, and the UKPDS demonstrated that tight blood pressure control reduced the risk of retinopathy progression by 34%. Blood pressure targets differ by diabetes type and the presence of complications:
-
For type 1 diabetes (NICE NG17): aim for below 135/85 mmHg; consider below 130/80 mmHg if albuminuria or multiple metabolic risk factors are present.
-
For type 2 diabetes (NICE NG136): generally below 140/90 mmHg in adults under 80 years, or below 150/90 mmHg in those aged 80 and over.
-
Where chronic kidney disease is present (NICE NG203), lower targets may be appropriate, particularly in the presence of significant albuminuria.
Other significant risk factors include:
-
Duration of diabetes — the longer a person has lived with diabetes, the greater the cumulative risk of retinopathy, regardless of current HbA1c
-
Dyslipidaemia — elevated serum lipids, particularly triglycerides, are associated with hard exudates and macular involvement; evidence from the FIELD and ACCORD Eye trials suggests fenofibrate may reduce the need for laser treatment in some patients with diabetic maculopathy, though this is not universally recommended
-
Pregnancy — diabetic retinopathy can worsen significantly during pregnancy, and women with pre-existing diabetes require enhanced retinal monitoring at the first antenatal appointment and throughout pregnancy, in line with NICE NG3
-
Nephropathy — the presence of diabetic kidney disease is a marker of generalised microvascular damage and correlates with retinopathy severity
-
Smoking — tobacco use impairs vascular health and is generally considered to have an adverse effect on vascular complications, though the evidence specifically linking smoking to retinopathy progression is less consistent than for other complications
-
Ethnicity — people of South Asian, African, or Caribbean heritage have higher rates of type 2 diabetes and may be at increased risk of complications
A holistic approach to diabetes management — addressing all modifiable risk factors, not HbA1c alone — offers the best protection against sight-threatening retinopathy.
Key sources: UKPDS BP control publications; NICE NG17; NICE NG136 (Hypertension in adults); NICE NG203 (Chronic kidney disease); NICE NG3 (Diabetes in pregnancy); FIELD trial; ACCORD Eye Study.
When to Seek an NHS Diabetic Eye Screening Referral
All people with diabetes aged 12 and over should attend annual NHS Diabetic Eye Screening; grades R2, R3, or M1 require Hospital Eye Services referral, and sudden visual symptoms need same-day urgent eye assessment.
The NHS Diabetic Eye Screening (DES) Programme offers annual retinal photography to all people aged 12 and over who have been diagnosed with diabetes. This programme is designed to detect retinopathy at an early, treatable stage, before symptoms develop. It is important to understand that diabetic retinopathy is often asymptomatic in its early stages — by the time visual symptoms appear, significant damage may already have occurred.
Patients should ensure they are registered with their local DES programme and attend every annual invitation. Screening results are graded, and the appropriate follow-up depends on the grade:
-
Background retinopathy (R1) — mild changes that do not require immediate ophthalmology referral; patients are typically recalled within the DES programme at a shorter interval for monitoring.
-
Pre-proliferative retinopathy (R2), proliferative retinopathy (R3), or maculopathy (M1) — these grades require referral to Hospital Eye Services for further assessment and possible treatment. Timescales for referral are determined by the DES programme and the grading result.
There are also specific circumstances in which urgent or additional review is warranted outside of routine screening:
-
Sudden change in vision, large increase in floaters, flashing lights, or a shadow or curtain across the visual field — these may indicate vitreous haemorrhage or retinal detachment, both of which are sight-threatening emergencies requiring same-day urgent assessment at an eye casualty department, A&E, or via NHS 111 for triage
-
Rapid or significant HbA1c reduction — patients undergoing major glycaemic improvement should discuss the need for closer retinal monitoring with their diabetes care team or DES programme
-
Pregnancy in a woman with pre-existing diabetes — enhanced screening is recommended at the first antenatal appointment and throughout pregnancy, in line with NICE NG3
If you are concerned about your eye health between screening appointments, contact your diabetes care team or GP promptly, or call NHS 111 for urgent advice. For acute visual symptoms, seek same-day urgent eye care without delay.
If you experience any suspected side effects from medicines used to manage your diabetes or related conditions, these can be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.
Early detection and intervention — combined with sustained HbA1c reduction and cardiovascular risk factor management — remain the most effective strategies for preserving vision in people living with diabetes.
Key sources: NHS.UK Diabetic Eye Screening page; NHSE DES operational guidance (grading and referral criteria); NICE NG3 (Diabetes in pregnancy); MHRA Yellow Card Scheme.
Frequently Asked Questions
How much does a 1% HbA1c reduction reduce the risk of diabetic retinopathy?
According to UKPDS 35, each 1% reduction in HbA1c is associated with approximately a 37% reduction in the risk of microvascular complications, which prominently includes diabetic retinopathy. This underscores the importance of sustained glycaemic control in protecting eye health.
Can lowering HbA1c too quickly make diabetic retinopathy worse?
Yes, rapid HbA1c reduction — particularly in patients with longstanding poor glycaemic control — has been associated with a transient, short-term worsening of diabetic retinopathy, as observed in the DCCT. Diabetes care teams should consider closer retinal monitoring when implementing major glycaemic improvements.
How often should people with diabetes have their eyes screened for retinopathy in the UK?
The NHS Diabetic Eye Screening Programme invites all people aged 12 and over with diabetes for annual retinal photography to detect retinopathy at an early, treatable stage. Those with higher-grade findings are referred to Hospital Eye Services, and pregnant women with pre-existing diabetes require enhanced screening throughout pregnancy.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
